Loading
KB
KALA BIO, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 31 Dec 2024.
KALA BIO, Inc.: what insiders have been doing
KALA BIO, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). 5 insiders have disclosed 5 filings since 18 October 2025.
Only sales appear on the open market, 5 sales in all totalling €213k, filed by 5 insiders. At €108k, the sale published on 24 October 2025 by Iwicki Mark T is the largest of the period.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 5 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 2 purchases and 53 sales. The 10-K for the year ended 31 December 2025 shows -27.0 m USD of net income.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
119
Thresholds
n/a
Buy Volume
€2M
2 ops. · all time
Sell Volume
€2M
53 ops. · all time
Who traded when
BuySaleBaker Bros. Advisors LP2 buys1 sale
Darius Kharabi3 sales
Mark T. Iwicki3 sales
Mary Reumuth3 sales
Romulus K. Brazzell3 sales
Todd Bazemore3 sales
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
Income statement
Net income-24.1M
Last declaration on 24 October 2025
Declarations119 total
154,894 shares@ US$0.8136.2% of flowCommon StockSEC:0001415537-25-000004:0
20,806 shares@ US$0.8326.1% of flowCommon StockSEC:0001893729-25-000003:0
32,230 shares@ US$0.8331.4% of flowCommon StockSEC:0001710969-25-000003:0
47,768 shares@ US$0.8337.2% of flowCommon StockSEC:0001605767-25-000004:0
46,748 shares@ US$0.8333.6% of flowCommon StockSEC:0001298079-25-000003:0
21,376 shares@ US$1.59591.5% of flowCommon StockSEC:0001193125-25-228536:0
4,511 shares@ US$4.0127.3% of flowCommon StockSEC:0001415889-25-018321:0
3,631 shares@ US$4.0117.1% of flowCommon StockSEC:0001415889-25-018320:0
4,058 shares@ US$4.0115.3% of flowCommon StockSEC:0001415889-25-018319:0
5,251 shares@ US$4.0118.3% of flowCommon StockSEC:0001415889-25-018318:0
13,227 shares@ US$4.0115.3% of flowCommon StockSEC:0001415889-25-018317:0
2,450 shares0Common StockSEC:0001415889-25-017614:0
2,450 shares0Common StockSEC:0001415889-25-017613:0
3,050 shares0Common StockSEC:0001415889-25-017611:0
2,450 shares0Common StockSEC:0001415889-25-017616:0
2,450 shares0Common StockSEC:0001415889-25-017615:0
2,450 shares0Common StockSEC:0001415889-25-017612:0
730 shares@ US$3.744.2% of flowCommon StockSEC:0001415889-25-015681:0
2,850 shares@ US$3.7412.7% of flowCommon StockSEC:0001415889-25-015680:0
3,390 shares@ US$3.7412.1% of flowCommon StockSEC:0001415889-25-015679:0
3,687 shares@ US$3.7412.2% of flowCommon StockSEC:0001415889-25-015678:0
10,866 shares@ US$3.7412.0% of flowCommon StockSEC:0001415889-25-015677:0
10,100 shares0Common StockSEC:0001415889-25-001061:0
10,100 shares0Common StockSEC:0001415889-25-001062:0
22,100 shares0Common StockSEC:0001415889-25-001060:0
25 of 119 declarations
About KALA BIO, Inc.
KALA BIO, Inc. is a biopharmaceutical company focused on developing innovative treatments for eye diseases. It is listed on NASDAQ under the ticker KALA.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
